Pavlo Kravchun

Pavlo Kravchun

Auto-generated profile, based on publicly available information

Pavlo Kravchun

Kharkiv National Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in The Journal of V. N. Karazin Kharkiv National University, Series "Medicine"
Verified
Journal Article
Open access
PDF file
KBK.M. Borovyk
K.M. Borovyk
PKP.н. Kravchun
P.н. Kravchun
OKO.I. Kadykova
O.I. Kadykova
ОКО.і. Кадикова
О.і. Кадикова
Background. The problem of lipid metabolism disorders in patients with coronary artery disease and chronic heart failure, especially with concomitant type 2 diabetes mellitus and obesity, is highly relevant due to their high prevalence, significant contribution to cardiovascular morbidity and mortality, and the complexity of correction. Researching the role of catestatin in this complex clinical scenario opens new perspectives for understanding the pathogenesis of dyslipidemia and developing potential therapeutic strategies. Purpose – to evaluate the levels of lipid metabolism parameters, serum catestatin, and to establish correlations between the studied parameters in patients with coronary artery disease and chronic heart failure depending on concomitant metabolic pathologies such as type 2 diabetes mellitus and obesity. Materials and Methods. The study included 225 patients with chronic heart failure and coronary artery disease. Patients were divided into four groups: Group 1 – chronic heart failure with coronary artery disease, concomitant type 2 diabetes mellitus and obesity (n=75), Group 2 – chronic heart failure with coronary artery disease and concomitant type 2 diabetes mellitus (n=50), Group 3 – chronic heart failure with coronary artery disease and concomitant obesity (n=50), Group 4 – chronic heart failure of ischemic origin without metabolic disorders (n=50). The levels of catestatin, total cholesterol, high-density lipoprotein cholesterol, triglycerides, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol and the atherogenic coefficient were determined. Results. Patients in Group 1 showed a significant increase in total cholesterol, triglycerides, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, the atherogenic coefficient and a decrease in high-density lipoprotein cholesterol compared to other groups (p < 0.05). Catestatin levels were the lowest in Group 1 and significantly different from other groups (p < 0.05). Significant correlations were found between catestatin levels and lipid metabolism parameters: negative correlations with triglycerides, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, the atherogenic coefficient and a positive correlation with high-density lipoprotein cholesterol levels. Conclusions. Patients with chronic heart failure and coronary artery disease complicated by type 2 diabetes mellitus and obesity exhibit the most pronounced lipid profile disorders and a significant decrease in catestatin levels. The data obtained indicate an important role of catestatin in the regulation of lipid metabolism and emphasize the need for a comprehensive approach to the treatment of this category of patients.

21 May 2026 in Marmara Medical Journal
Verified
Journal Article
Closed access
PKPavlo Kravchun
Pavlo Kravchun
IDInna Dunaeva
Inna Dunaeva
FLFrida Leontyeva
Frida Leontyeva
OPOlena Povelichenko
Olena Povelichenko
VDValentyna Dielievsks
Valentyna Dielievsks
Objective: Dysmetabolic nephropathies are characterized by disturbances in oxalate, urate and phosphate metabolism and have beensuggested as triggering factors for bone and joint pathology. The aim of this study was determine the frequency of dysmetabolicnephropathies in patients with bone and joint pathology and to compare the laboratory parameters between patients with dysmetabolicnephropathy and controls.Patients and Methods: Patients with bone and joint pathology (coxarthrosis, gonarthrosis, ligamentum ruptures, and bone fractures)were enrolled in the study. Dysmetabolic nephropathy (characterized by hyperoxaluria, uraturia or phosphaturia) was revealed in9% of patients with bone and joint pathology. Sixty-one patients without dysmetabolic nephropathy served as a control group. Thepatients underwent general clinical and biochemical examinations.Results: The persons with bone and joint pathology and the presence of dysmetabolic nephropathy demonstrated a prevalence ofhyperoxaluria (59%) with less frequency of uraturia (25.7%) and phosphaturia (15.1%). Hyperoxaluria was associated with a highincidence of ligamentum ruptures and bone fractures (21.6%). The persons with hyperoxaluria demonstrated higher levels ofeosinophils, platelets, white blood cells (WBCs), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), thymol probe, andserum alkaline phosphatase. The persons with dysmetabolic nephropathy showed higher levels of WBCs, ESR, alkaline phosphatase,creatinine, thymol probe, and CRP (P

11 April 2021 in Inter Collegas
Verified
Journal Article
Closed access
PDF file
PKPavlo Kravchun
Pavlo Kravchun
OKOlga Kadykova
Olga Kadykova
UHUliana Herasymchuk
Uliana Herasymchuk
Introduction. Well-known the fact that obesity, especially its abdominal (visceral) form, is one of the most important risk factors for hypertension. The purpose: to determine the level of adiponutrin in patients with hypertension and obesity. Assess how the degree of hypertension and obesity affects the level of adiponutrin in our patients with this comorbid pathology. Materials and methods. The study included 58 patients with hypertension. Grade 1 was diagnosed in 12 (20.69%), grade 2 - in 16 (27.59%), grade 3 - in 30 (51.72%) examined patients. Of these, 32 women and 26 men aged 32 to 79 years (mean age 57.5 ± 10.11 years). Patients underwent anthropometric measurements, assessed lipid profile and changes in carbohydrate metabolism, adiponutrin levels. Results. The level of adiponutrin in all groups of hypertensive patients with overweight and obesity was significantly increased compared to the control group, but the degree of hypertension did not affect the level of adiponutrin. However, the concentration of the latter in the serum gradually increases according to the duration of hypertension. In addition, the level of adiponutrin increased depending on the degree of obesity, which, in turn, was confirmed by a reliable direct linear relationship between adiponutrin and body mass index. Conclusions. Based on the data obtained, adiponutrin can be considered as a marker of metabolic syndrome.

23 December 2025 in Pathologia
Verified
Journal Article
Open access
KBK. M. Borovyk
K. M. Borovyk
OKO. I. Kadykova
O. I. Kadykova
PKP. H. Kravchun
P. H. Kravchun
VBV. D. Babadzhan
V. D. Babadzhan
NRN. H. Ryndina
N. H. Ryndina
ASA. O. Sypalo
A. O. Sypalo
The aim: to evaluate serum nesfatin-1 levels and their correlation with lipid profile parameters in patients with ischemic heart failure (HF) with and without concomitant metabolic comorbidities such as type 2 diabetes mellitus (T2DM) and obesity. Materials and methods. The study included 225 patients with HF due to ischemic heart disease, divided into four groups: Group 1 (n = 75) – with T2DM and obesity; Group 2 (n = 50) – with T2DM; Group 3 (n = 50) – with obesity; Group 4 (n = 50) – without metabolic disturbances. Serum nesfatin-1 levels were determined using an enzyme-linked immunosorbent assay (ELISA). Biochemical analysis included measurements of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very-low-density lipoprotein cholesterol (VLDL-C), as well as calculation of the atherogenic coefficient (AC). Correlation analysis was performed using Spearman’s rank correlation test. Results. In patient groups with concomitant metabolic comorbidities (Groups 1, 2, and 3), statistically significant inverse correlations were observed between serum nesfatin-1 levels and pro-atherogenic lipids (TC, TG, LDL-C, VLDL-C), along with a significant direct correlation with the anti-atherogenic fraction (HDL-C). In these groups, higher nesfatin-1 levels were associated with a significant decrease in TC (17.6–24.6 %), TG (11.3–49.6 %), LDL-C (29.1–65.0 %), and AC (49.7–59.6 %), alongside an increase in HDL-C (23.1–44.7 %). In contrast, in Group 4 (patients without metabolic disturbances), the effect of nesfatin-1 on the lipid profile was less pronounced. While TG levels decreased significantly (by 28.6 %), other parameters (TC, HDL-C, LDL-C, AC) showed no statistically significant changes or only minimal variations. These findings suggest a context-dependent role of nesfatin-1 in lipid metabolism, with more pronounced effects in the presence of metabolic comorbidities. Conclusions. Elevated serum nesfatin-1 levels are associated with an improved lipid profile in patients with ischemic HF complicated by type 2 diabetes mellitus and/or obesity, suggesting a potential protective role of this peptide in the presence of metabolic comorbidities. In contrast, in patients without metabolic disturbances, this effect is markedly attenuated or absent. These findings underscore the need for further investigation into the underlying mechanisms of nesfatin-1 action across different clinical populations.

30 December 2025 in Ukrainian Therapeutical Journal
Verified
Journal Article
Open access
PDF file
KBK. M. Borovyk
K. M. Borovyk
PKP. H. Kravchun
P. H. Kravchun
OKO. I. Kadykova
O. I. Kadykova
ASA. O. Sypalo
A. O. Sypalo
ОКО. І. Кадикова
О. І. Кадикова
Objective to conduct a comparative assessment of the effectiveness of personalized treatment strategies for patients with chronic heart failure of ischemic origin with concomitant type 2 diabetes mellitus and obesity. Materials and methods. The study involved 75 patients with chronic heart failure due to coronary artery disease with concomitant type 2 diabetes mellitus and obesity. The average age of patients was 63.44±2.06 years. For a comparative analysis of the various modulators of neurohormonal vasoconstrictor systems effectiveness, the examined patientswith heart failure were divided into 2 groups, depending on the proposed therapy (a combination of valsartan and sacubitril (n = 39) or valsartan alone (n = 36)). Results. All groups showed a decrease in galectin-3, nesfatin-1 and N-terminal fragment of pro-B-type natriuretic peptide serum levels, improvement in chronic heart failure functional class, increase in left ventricle ejection fraction, decrease in insulin resistance, positive changes in the lipid profile, and improvement in quality of life. A comparative analysis of two treatment strategies showed that in the 1st group, which received a combination of valsartan and sacubitril, significantly lower levels of galectin-3, nesfatin-1, and N-terminal fragment of pro-B-type natriuretic peptide and a higher level of catestatin were observed, as well as positive changes in the morpho-functional state of the myocardium compared to the 2nd group, which received only valsartan. Conclusions. The obtained results confirm the benefits of the combination of neprilysin inhibitor and angiotensin II receptor blocker in the treatment of chronic heart failure, especially in patients withcomorbidities such as coronary artery disease, type 2 diabetes mellitus, and obesity.

1 January 2026 in SCRIPTA MEDICA
Verified
Journal Article
Open access
PDF file
PKPavlo Kravchun
Pavlo Kravchun
FLFrida Leontyeva
Frida Leontyeva
OPOlena Povelichenko
Olena Povelichenko
VDValentyna Dielievsks
Valentyna Dielievsks
Background/Aim: ABO discrepancies remain an important challenge in transfusion medicine because discordant forward and reverse grouping results may require additional serological techniques and testing under different temperature and incubation conditions. Accurate investigation of such discrepancies is essential for selection of appropriate transfusion and transplantation strategies. This study aimed to investigate suspected weak A and B phenotypes in two individuals with ABO discrepancies and to assess epidermal mixed agglutination reaction (MAR) as an additional investigational method.Methods: Two individuals with discordant forward and reverse ABO grouping results were investigated using routine and prolonged agglutination testing, adsorption studies, secretor-status determination, epidermal MAR, a lymphocytotoxicity assay and testing for autoimmune acid-reactive warm and cold haemolysins. Prolonged reverse grouping was performed at 4 °C and 37 °C. Adsorption studies were conducted using erythrocytes, leucocytes, saliva or mucosal cells and epidermal cells.Results: In Person A, routine forward grouping showed no agglutination with anti-A or anti-B reagents, whereas reverse grouping demonstrated strong reactivity with A reagent erythrocytes and no reactivity with B reagent erythrocytes. After 1 h of prolonged incubation, the serum agglutinated A erythrocytes at 4 °C (4+) and 37 °C (2+) and B erythrocytes at both 4 °C and 37 °C (3+). Adsorption with anti-A serum reduced agglutination after exposure to the individual's erythrocytes, leucocytes, mucosal cells and epidermal cells. A blood-group substance was detected in saliva and epidermal cells adsorbed anti-A antibodies in MAR. Autoimmune acid-agglutinating antibodies were not detected. The combined serological findings were consistent with a suspected Ael phenotype. In Person K, routine forward grouping showed no agglutination with anti-A or anti-B reagents, while reverse grouping demonstrated reactivity with A erythrocytes but not with B erythrocytes. Following 1 h of prolonged incubation, A erythrocytes were agglutinated at 4 °C and 37 °C (4+ at both temperatures), whereas B erythrocytes were agglutinated at 4 °C (3.5+) and 37 °C (3+). Adsorption with anti-B serum reduced agglutination after exposure to the individual's erythrocytes, leucocytes and epidermal cells. B blood-group substance was detected in saliva and epidermal cells adsorbed anti-B antibodies in MAR. These findings were consistent with a suspected Bel phenotype.Conclusion: These two cases illustrate complex ABO discrepancies that could not be resolved by routine forward and reverse grouping alone. Prolonged incubation, adsorption studies, secretor-status determination and epidermal MAR provided complementary evidence of very weak Aand B-related antigenic activity. The combined findings were consistent with suspected Ael and Bel phenotypes; however, definitive subgroup assignments were not established. Epidermal MAR may represent an additional investigational approach in selected cases of suspected weak ABO phenotypes, but its diagnostic performance and clinical utility require validation in larger studies.